Answers are grounded in this paper and cite their sources.
Review summarizes endothelin-1's impact on hypertension in populations at risk, suggesting its therapeutic potential.
Endothelin-1 is a vasoconstrictor peptide originating in the endothelium.It is a highly potent vascular regulator involved in the pathophysiology of hypertension.People of African American descent, obesity, and resistant hypertension are prone to cardiovascular events, according to studies that have found high levels of endothelin-1 in these subjects.Although information about its circulating levels in essential hypertension is contradictory, data support its relevance as a local agent in vascular walls.The design of endothelin receptor antagonists validates endothelin's pathophysiological role and allows new therapeutic options to emerge.This review summarizes how endothelin-1 is involved in several factors that contribute to endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure control, all key processes in hypertension.It also emphasizes this peptide's potential as a biomarker and therapeutic target to optimize the detection and treatment of this disease.
No takes yet. Share an insight, caveat, or question.
Manzur-Jattin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: